With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent
PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies
As fears grow over subject-matter eligibility and technological convergence threatens to reshape the competitive landscape, patent strategy has become even more crucial for medical device companies
In a rare public appearance, the Chinese telecom’s founder and CEO, Ren Zhengfei, reaffirms commitment to respect third-party patents and explains why paying more than the competition will keep his company ahead
The court’s decision in Helsinn Healthcare v Teva Pharmaceutical will disappoint the many biopharma businesses that depend on pre-marketing drug development collaboration
New rules on preliminary injunctions from the Supreme People's Court could have a significant affect on IP litigation in China – not least the long-running battle between Apple and Qualcomm.
Given the difficulty that pharmaceutical products face when it comes to reaching market, Arrow declarations can be a crucial means of slicing through the knot.
Appointment of experienced patent litigator to local bench and Austin's growing reputation as a tech hub must be weighed against defendant-friendly rules
Draft changes would entitle women inventors and small businesses to expedited patent examination, but some see a backdoor for big business to take advantage too
Services at the FDA could “grind to a halt” in a matter weeks if the budget deadlock between President Trump and Democrats continues. Major disruption at the USPTO and in the courts may also be on the cards.
Lawsuit filings and inter partes review petitions both fell in 2018, but operating companies’ share of the action was on the rise
In exclusive interview with IAM, Bill Merritt claims that ADR can prevent current licence conflict with Huawei becoming a flashpoint in the US-China trade battle
After heavy trailing by the USPTO Director, agency proposes new details on issue of abstract ideas just as the Supreme Court turns its attention to “blockbuster” 101 Fed Circuit case
Reports say the top court upheld the patentability of novel genetically lab-engineered chemical entities like the company's blockbuster Bt cotton variety
Retrial ordered in Huawei v InterDigital; Apple representatives threatened with detention in continuing injunction flap; national IP appeals court opens doors and much more from the Middle Kingdom